Special Issue "Antivirals Against Poxviruses"
QuicklinksA special issue of Viruses (ISSN 1999-4915).
Deadline for manuscript submissions: 15 June 2010
Special Issue Editor
Guest Editor
Prof. Dr. Earl R. Kern
The University of Alabama at Birmingham, CHB 128, 1600 6th Avenue South, Birmingham, AL 35216, USA
E-Mail:
Published Papers
Special Issue Information
Dear Colleagues,
Although smallpox was eradicated about 30 years ago, there are continuing concerns regarding the intentional or accidental release of variola virus in a population that has little immunity due to the cessation of universal vaccination programs.
Additionally, the inadvertent importation of monkeypox virus into the United States through the sale of infected rodents reinforced the need for effective therapies that could be used during outbreaks of these infections. In response to these concerns, additional resources have been allocated to the research, discovery and development of new antiviral agents and significant advances have been achieved. At the present time there is no licensed drug for the treatment of any orthopoxvirus infection, however, cidofovir has been approved for use in the emergency treatment of smallpox outbreaks or in complications following vaccination. Two additional molecules, CMX001, an orally active analog of cidofovir, and ST-246, a small molecule, are highly active in vitro and in a variety of experimental orthopoxvirus infections in animals including non-human primates. Neither one has been approved due to the inability to conduct clinical studies for efficacy. This special issue will focus primarily on the development of these promising molecules and particularly on the use of animal model systems used to evaluate new antiviral drugs for treatment of orthopoxvirus infections in humans.
Prof. Dr. Earl R. Kern
Guest Editor
Submission
All manuscripts should be submitted to viruses@mdpi.org with a copy to the Guest Editor. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed Open Access monthly journal published by MDPI.
Keywords
- orthopoxvirus
- poxvirus
- antiviral
- animal model
- cidofovir
- CMX001
- ST-246
- variola virus
- monkeypox virus
- vaccinia virus
- cowpox virus
- rabbitpox virus
- ectromelia virus
Planned Papers
Title: Orthopoxviruses as agents of Emerging Diseases and Bioterror.
Author: Richard Whitley
Affiliation: University of Alabama at Birmingham, Birmingham, AL, USA; E-Mail: RWhitley@peds.uab.edu
Title: Historical Perspectives in the development of antiviral agents against poxviruses.
Author: Erik De Clercq
Affiliation: Rega Institute for Medical Research, Leuven, Belgium; E-Mail: erik.declercq@rega.kuleuven.ac.be
Title: Therapeutic vaccines and antibodies for treatment of orthopoxvirus infections.
Author: Stuart Isaacs
Affiliation: University of Pennsylvania, Philadelphia, PA, USA; E-Mail: isaacs@mail.med.upenn.edu
Title: Review of the activity of cidofovir against poxvirus infections. Author: Graciela Andries
Affiliation: Rega Institute for Medical Research, Leuven, Belgium; E-Mail: graciela.andrei@rega.kuleuven.be
Title: Synthesis and development of orally active lipid conjugates of nucleoside phosphonates.
Author: Karl Hostetler
Affiliation: University of San Diego/VA Hospital, San Diego, CA, USA; E-Mail: khostetl@ucsd.edu
Title: Treatment of vaccinia and cowpox virus infections in mice with CMX001 and ST-246.
Author: Debra Quenelle
Affiliation: University of Alabama at Birmingham, Birmingham, AL, USA; E-Mail: DQuenelle@peds.uab.edu
Title: Ectromelia virus infections of mice as a model for orthopoxvirus infections.
Author: Mark Buller
Affiliation: Saint Louis University, Saint Louis, MO, USA; E-Mail: bullerrm@slu.edu
Title: Use of the aerosol rabbitpox virus model for evaluation of anti-poxvirus agents.
Author: Chad Roy
Affiliation: Tulane University, New Orleans, LA, USA; E-Mail: croy@tulane.edu
Title: Activity of CMX001 in rabbits infected with rabbitpox.
Author: Richard Moyer
Affiliation: University of Florida, Gainesville, FL, USA; E-Mail: rmoyer@mgm.ufl.edu
Title: Synthesis, activity and development of 4′-thioIDU and other thiopyrimidine analogs against poxviruses.
Author: Mark Prichard
Affiliation: University of Alabama at Birmingham, Birmingham, AL, USA; E-Mail: MPrichard@peds.uab.edu
Title: Development of ST-246 for treatment of poxvirus infections.
Author: Dennis Hruby
Affiliation: Siga Corporation, Corvallis, OR, USA; E-Mail: dhruby@siga.com
Title: Development of CMX001 for the treatment of poxvirus infections.
Author: George Painter
Affiliation: Chimerix, Inc. Durham, NA, USA; E-Mail: gpainter@chimerix-inc.com
Last update: 1 March 2010